Biostem Technologies (BSEM) Q1 2026 earnings summary

Executive summary

• Completed a transformative acquisition in January 2026, integrating BioTissue surgical and wound care assets, expanding the direct sales force to 35 representatives, and shifting focus from physician office to hospital channel.

• Integration of acquired assets has been smooth, with minimal disruption and stable sales performance in the hospital business.

• Strategic priorities include integrating the acquisition, scaling the sales force, advancing the product roadmap (including 510(k) clearance), and executing a technology transfer for key products.

• Confidentially submitted Form 10 to the SEC and issued audited financials for 2024 and 2025, progressing toward uplisting to Nasdaq.

• Retired $3 million in principal and $2.3 million in accrued interest debt with GMA, and appointed a new Chief Legal and Compliance Officer.

Financial highlights

• Q1 2026 revenue was $6.1 million, above guidance of $5–6 million, but down from $10.1 million in the prior quarter and $16.0 million in Q1 2025.

• Hospital-based revenue was $5.4 million (87% of total); physician office revenue was $772,000.

• Gross profit was $3.8 million (61% margin), down from $9.8 million (97%) in the prior period.

• Operating expenses were $12.6 million, down from $17.3 million in the prior period, reflecting lower bad debt expense but higher costs from the acquisition and uplisting process.

• GAAP net loss was ($8.8 million) or ($0.52) per share, versus net income of $3.9 million or $0.23 per share in Q1 2025.

Outlook and guidance

• Full-year 2026 revenue guidance is $25–29 million, reflecting growth opportunities and ongoing operational transition.

• Sequential revenue growth expected each quarter, with Q2 as the first full quarter post-acquisition and further improvement anticipated in the second half of 2026.

• Hospital business growth to be driven by sales force expansion, GPO contract utilization, and new product introductions.

• Physician office market expected to stabilize and return to sequential revenue growth in H2 2026.